Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.

@article{Kane2010OlanzapineLI,
  title={Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.},
  author={J. Kane and H. Detke and D. Naber and G. Sethuraman and D. Lin and R. Bergstrom and D. McDonnell},
  journal={The American journal of psychiatry},
  year={2010},
  volume={167 2},
  pages={
          181-9
        }
}
OBJECTIVE The purpose of the present study was to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatment of schizophrenia. METHOD Outpatients with schizophrenia who had maintained stability on an oral regimen of olanzapine (10, 15, or 20 mg/day) for 4 to 8 weeks were randomly assigned to 24 weeks of double-blind treatment with "low" (150 mg every 2 weeks; N=140), "medium" (405 mg every 4 weeks; N=318), or "high" (300 mg every 2 weeks; N=141) doses… Expand

Paper Mentions

Interventional Clinical Trial
This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM… Expand
ConditionsSchizophrenic Disorders
InterventionDrug
Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine: A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia
Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching
Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 10 REFERENCES
Relapse and rehospitalization: comparing oral and depot antipsychotics.
  • N. Schooler
  • Medicine
  • The Journal of clinical psychiatry
  • 2003
A rating scale for drug-induced akathisia.
  • T. Barnes
  • Psychology, Medicine
  • The British journal of psychiatry : the journal of mental science
  • 1989
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS